Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI

Biomaterials

Volumn 33, Issue 5, 2012, Pages 1462-1476

  Yang, Yi Ping ^a   Chien, Yueh ^a,c   Chiou, Guang Yuh ^a,c   Cherng, Jong Yuh ^b   Wang, Mong Lien ^a   Lo, Wen Liang ^a,c   Chang, Yuh Lih ^a,c   Huang, Pin I ^a,c   Chen, Yi Wei ^a,c   Shih, Yang Hsin ^a,c   Chen, Ming Teh ^a,c   Chiou, Shih Hwa ^a,c  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Drug resistance; Glioblastoma; MiR145; Polyurethane short branch polyethylenimine

Indexed keywords

BRAIN TUMORS; CANCER STEM CELLS; DRUG-RESISTANCE; GLIOBLASTOMAS; IN-VIVO; MALIGNANT CANCERS; MALIGNANT GLIOMA; MICRORNAS; MIR145; ORTHOTOPIC; POLYETHYLENIMINES; RT-PCR ANALYSIS; SMALL RNA; SURVIVAL RATE; TEMOZOLOMIDE; THERAPEUTIC STRATEGY; TUMORIGENESIS;

BRAIN; DISEASES; GENE EXPRESSION; ONCOGENIC VIRUSES; POLYMERASE CHAIN REACTION; POLYURETHANES; RNA; STEM CELLS; TUMORS;

RADIOTHERAPY;

CD133 ANTIGEN; MESSENGER RNA; MICRORNA; MICRORNA 145; OCTAMER TRANSCRIPTION FACTOR 4; POLYETHYLENEIMINE; POLYURETHAN; TEMOZOLOMIDE; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER STEM CELL; CARCINOGENESIS; CHEMORADIOTHERAPY; CLINICAL ARTICLE; DOWN REGULATION; DRUG RESISTANCE; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE;

3' UNTRANSLATED REGIONS; AGED; BASE SEQUENCE; CELL TRANSFORMATION, NEOPLASTIC; DACARBAZINE; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TRANSFER TECHNIQUES; GLIOBLASTOMA; HUMANS; MALE; MICRORNAS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASTIC STEM CELLS; OCTAMER TRANSCRIPTION FACTOR-3; POLYETHYLENEIMINE; POLYURETHANES; RADIATION TOLERANCE; SOXB1 TRANSCRIPTION FACTORS;

MUS;

EID: 83355166283     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.10.071     Document Type: Article

References (58)

1. Boiani M., Scholer H.R. Regulatory networks in embryo-derived pluripotent stem cells. Nat Rev Mol Cell Biol 2005, 6(11):872-884.
2. Pesce M., Wang X., Wolgemuth D.J., Scholer H. Differential expression of the Oct-4 transcription factor during mouse germ cell differentiation. Mech Dev. 1998, 71(1-2):89-98.
3. Du Z., Jia D., Liu S., Wang F., Li G., Zhang Y., et al. Oct4 is expressed in human gliomas and promotes colony formation in glioma cells. Glia 2009, 57(7):724-733.
4. Huang Z., Cheng L., Guryanova O.A., Wu Q., Bao S. Cancer stem cells in glioblastoma-molecular signaling and therapeutic targeting. Protein Cell 2010, 1(7):638-655.
5. Furnari F.B., Fenton T., Bachoo R.M., Mukasa A., Stommel J.M., Stegh A., et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007, 21(21):2683-2710.
6. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444(7120):756-760.
7. Clarke M.F., Dick J.E., Dirks P.B., Eaves C.J., Jamieson C.H., Jones D.L., et al. Cancer stem cells-perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 2006, 66(19):9339-9344.
8. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003, 63(18):5821-5828.
9. Mizrak D., Brittan M., Alison M.R. CD133: molecule of the moment. J Pathol 2008, 214(1):3-9.
10. Ricci-Vitiani L., Lombardi D.G., Pilozzi E., Biffoni M., Todaro M., Peschle C., et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445(7123):111-115.
11. Miki J., Furusato B., Li H., Gu Y., Takahashi H., Egawa S., et al. Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res 2007, 67(7):3153-3161.
12. Ma S., Chan K.W., Hu L., Lee T.K., Wo J.Y., Ng I.O., et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007, 132(7):2542-2556.
13. Zhu L., Gibson P., Currle D.S., Tong Y., Richardson R.J., Bayazitov I.T., et al. Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature 2009, 457(7229):603-607.
14. Esquela-Kerscher A., Slack F.J. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006, 6(4):259-269.
15. Sempere L.F., Liu X., Dmitrovsky E. Tumor-suppressive microRNAs in lung cancer: diagnostic and therapeutic opportunities. Scientific World J 2009, 9:626-628.
16. Croce C.M. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009, 10(10):704-714.
17. Chan J.A., Krichevsky A.M., Kosik K.S. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005, 65(14):6029-6033.
18. Chen Y.C., Hsu H.S., Chen Y.W., Tsai T.H., How C.K., Wang C.Y., et al. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS One 2008, 3(7):e2637.
19. Bass A.J., Watanabe H., Mermel C.H., Yu S., Perner S., Verhaak R.G., et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009, 41(11):1238-1242.
20. Huse J.T., Brennan C., Hambardzumyan D., Wee B., Pena J., Rouhanifard S.H., et al. The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev 2009, 23(11):1327-1337.
21. Malzkorn B., Wolter M., Liesenberg F., Grzendowski M., Stuhler K., Meyer H.E., et al. Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol 2010, 20(3):539-550.
22. Kefas B., Godlewski J., Comeau L., Li Y., Abounader R., Hawkinson M., et al. MicroRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res 2008, 68(10):3566-3572.
23. Li T., Li D., Sha J., Sun P., Huang Y. MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commun 2009, 383(3):280-285.
24. Michael M.Z., OC S.M., van Holst Pellekaan N.G., Young G.P., James R.J. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 2003, 1(12):882-891.
25. Iorio M.V., Visone R., Di Leva G., Donati V., Petrocca F., Casalini P., et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007, 67(18):8699-8707.
26. Iorio M.V., Ferracin M., Liu C.G., Veronese A., Spizzo R., Sabbioni S., et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005, 65(16):7065-7070.
27. Akao Y., Nakagawa Y., Kitade Y., Kinoshita T., Naoe T. Downregulation of microRNAs-143 and -145 in B-cell malignancies. Cancer Sci 2007, 98(12):1914-1920.
28. Schepeler T., Reinert J.T., Ostenfeld M.S., Christensen L.L., Silahtaroglu A.N., Dyrskjot L., et al. Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res 2008, 68(15):6416-6424.
29. Xu N., Papagiannakopoulos T., Pan G., Thomson J.A., Kosik K.S. MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell 2009, 137(4):647-658.
30. Krutzfeldt J., Rajewsky N., Braich R., Rajeev K.G., Tuschl T., Manoharan M., et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005, 438(7068):685-689.
31. Kota J., Chivukula R.R., O'Donnell K.A., Wentzel E.A., Montgomery C.L., Hwang H.W., et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009, 137(6):1005-1017.
32. Ma L., Reinhardt F., Pan E., Soutschek J., Bhat B., Marcusson E.G., et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol 2010, 28(4):341-347.
33. Thomas C.E., Ehrhardt A., Kay M.A. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 2003, 4(5):346-358.
34. Guan J., Fujimoto K.L., Sacks M.S., Wagner W.R. Preparation and characterization of highly porous, biodegradable polyurethane scaffolds for soft tissue applications. Biomaterials 2005, 26(18):3961-3971.
35. Shau M.D., Tseng S.J., Yang T.F., Cherng J.Y., Chin W.K. Effect of molecular weight on the transfection efficiency of novel polyurethane as a biodegradable gene vector. J Biomed Mater Res A 2006, 77(4):736-746.
36. Tseng S.J., Tang S.C., Shau M.D., Zeng Y.F., Cherng J.Y., Shih M.F. Structural characterization and buffering capacity in relation to the transfection efficiency of biodegradable polyurethane. Bioconjug Chem 2005, 16(6):1375-1381.
37. Hung W.C., Shau M.D., Kao H.C., Shih M.F., Cherng J.Y. The synthesis of cationic polyurethanes to study the effect of amines and structures on their DNA transfection potential. J Control Release 2009, 133(1):68-76.
38. Liu X.Y., Ho W.Y., Hung W.J., Shau M.D. The characteristics and transfection efficiency of cationic poly (ester-co-urethane) - short chain PEI conjugates self-assembled with DNA. Biomaterials 2009, 30(34):6665-6673.
39. Wang C.H., Chiou S.H., Chou C.P., Chen Y.C., Huang Y.J., Peng C.A. Photothermolysis of glioblastoma stem-like cells targeted by carbon nanotubes conjugated with CD133 monoclonal antibody. Nanomedicine 2011, 7(1):69-79.
40. + cells: improvement in radiotherapeutic effects. Laboratory investigation. J Neurosurg 2011, 114(3):651-662.
41. Lee J., Kotliarova S., Kotliarov Y., Li A., Su Q., Donin N.M., et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006, 9(5):391-403.
42. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., et al. Identification of human brain tumour initiating cells. Nature 2004, 432(7015):396-401.
43. Chiou S.H., Kao C.L., Chen Y.W., Chien C.S., Hung S.C., Lo J.F., et al. Identification of CD133-positive radioresistant cells in atypical teratoid/rhabdoid tumor. PLoS One 2008, 3(5):e2090.
44. Wang X.Q., Ongkeko W.M., Chen L., Yang Z.F., Lu P., Chen K.K., et al. Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway. Hepatology 2010, 52(2):528-539.
45. Hunter J.J., Parslow T.G. A peptide sequence from Bax that converts Bcl-2 into an activator of apoptosis. J Biol Chem 1996, 271(15):8521-8524.
46. Dehdashti A.R., Hegi M.E., Regli L., Pica A., Stupp R. New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy. Neurosurg Focus 2006, 20(4):E6.
47. Stupp R., Hegi M.E., Gilbert M.R., Chakravarti A. Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 2007, 25(26):4127-4136.
48. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352(10):987-996.
49. Hirschmann-Jax C., Foster A.E., Wulf G.G., Nuchtern J.G., Jax T.W., Gobel U., et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A 2004, 101(39):14228-14233.
50. Monzani E., Facchetti F., Galmozzi E., Corsini E., Benetti A., Cavazzin C., et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 2007, 43(5):935-946.
51. + cancer stem cells in glioblastoma. Mol Cancer 2006, 5:67.
52. Ji Q., Hao X., Zhang M., Tang W., Yang M., Li L., et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One 2009, 4(8):e6816.
53. Wang X., Han L., Zhang A., Wang G., Jia Z., Yang Y., et al. Adenovirus-mediated shRNAs for co-repression of miR-221 and miR-222 expression and function in glioblastoma cells. Oncol Rep 2011, 25(1):97-105.
54. Ghods A.J., Irvin D., Liu G., Yuan X., Abdulkadir I.R., Tunici P., et al. Spheres isolated from 9L gliosarcoma rat cell line possess chemoresistant and aggressive cancer stem-like cells. Stem Cells 2007, 25(7):1645-1653.
55. Schmitz M., Temme A., Senner V., Ebner R., Schwind S., Stevanovic S., et al. Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy. Br J Cancer 2007, 96(8):1293-1301.
56. Gangemi R.M., Griffero F., Marubbi D., Perera M., Capra M.C., Malatesta P., et al. SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells 2009, 27(1):40-48.
57. Koster R., di Pietro A., Timmer-Bosscha H., Gibcus J.H., van den Berg A., Suurmeijer A.J., et al. Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. J Clin Invest 2010, 120(10):3594-3605.
58. Jeon H.M., Sohn Y.W., Oh S.Y., Kim S.H., Beck S., Kim S., et al. ID4 imparts chemoresistance and cancer stemness to glioma cells by derepressing miR-9*-mediated suppression of SOX2. Cancer Res 2011, 71(9):3410-3421.